您好,欢迎您

【2021 WCLC】“Mini Oral Session”中国好声音抢先一览!

2021年08月10日
来源:肿瘤资讯

2021年世界肺癌大会(WCLC)将于9月8日至14日以全球虚拟网络会议的形式隆重召开,作为世界上最大的肺癌和其他胸部恶性肿瘤会议,WCLC吸引着全球专家学者的目光,最新前沿进展令人目接不暇。WCLC日程目前已经公布,“Mini Oral Session”共计17个,多位中国学者将在其中11个专场汇报最新研究成果。【肿瘤资讯】带您抢先一览!

微信图片_20210810135340.jpg

“Mini Oral Session”的中国好声音

专场:MA01 - Multimodality Management of Advanced Lung Cancer(2021.9.8)

报告标题:MA01.05 - Sintilimab, SBRT and GM-CSF for Advanced NSCLC: Safety Run-in Results of a Prospective, Multicenter, Phase II Trial

演讲者:Jianjiao Ni

jianjiao Ni.png

专场:MA02 - RET and Novel Combinations of Osimertinib(2021.9.8)

报告标题:MA02.01 - Efficacy and Safety of Selpercatinib in Chinese Patients With RET Fusion-Positive Non-Small Cell Lung Cancer: A Phase 2 Trial

演讲者:陆舜教授,上海市交通大学附属胸科医院

报告标题:MA02.02 - Efficacy and Safety of Pralsetinib in Chinese Patients with Advanced RET Fusion+ Non-Small Cell Lung Cancer

演讲者:周清教授,广东省肺癌研究所,广东省人民医院

报告标题:MA02.06 - Phase 1b Study of Pelcitoclax (APG-1252) in Combination With Osimertinib in Patients With EGFR TKI-Resistant NSCLC

演讲者:张力教授,中山大学肿瘤防治中心

2.png3.png

专场:MA03 - Biomarkers for Immunotherapy: Are All Relevant?(2021.9.8)

报告标题:MA03.06 - ctDNA Mass-Adjusted bTMB as a Predictive Biomarker in NSCLC Patients Receiving PD-(L)1 Inhibitors

演讲者:Wei Nie

报告标题:MA03.07 - Interferon-Gamma Mediated Immune Evasion: A Potential Mechanism of Resistance to Immunotherapy in Non-Small Cell Lung Cancer

演讲者:Fasheng Li

4.png

专场:MA04 - Current Status and Future Prospects of Pleural Mesothelioma and Thymoma(2021.9.8)

报告标题:MA04.02 - Characteristics of Genomic Alterations in Chinese Patients with Thymic Epithelial Tumors

演讲者:范兴龙,山东大学齐鲁医院

5.png

专场:MA07 - Liquid Biopsy Applications for Immuno-oncology, Targeted Therapies, and Early Stage NSCLC(2021.9.9)

报告标题:MA07.07 - High Sensitivity of Detecting Stage I Lung Cancer Using Genome-wide Multi-dimensional Fragmentomic Profiles of Cell Free DNA

演讲者:郭伟,山西省肿瘤医院

6.png

专场:MA08 - Driver Mutations and Immune Profiles in Early Stage NSCLC(2021.9.9)

报告标题:MA08.05 - Integrating Genomic and Transcriptomic Features Predict the Recurrence Risk of Stage IA Non-Small Cell Lung Cancer

演讲者:Shirong Zhang

报告标题:MA08.07 - Immune Characteristics Associated With Lymph Node Metastasis in Early-Stage NSCLC Discovered via T Cell Receptor Repertoires Sequencing

演讲者:李敏教授,中南大学湘雅医院

7.png8.png

专场:MA09 - Predictive Markers for Immunotherapy(2021.9.12)

报告标题:MA09.03 - Peripheral CD8+ T Cells Predicts Immune-Related Adverse Events and Survival in Advanced Non-Small Cell Lung Cancer Treated With Immunotherapy

演讲者:Kan Wu

9.png

专场:MA11 - New Biological Insights for Targeted Therapies(2021.9.12)

报告标题:MA11.02 - Targeting HER2 Exon 20–Mutant Lung Adenocarcinoma with a Novel Tyrosine Kinase Inhibitor, Mobocertinib

演讲者:Han Han

报告标题:Phase Separation of EML4-ALK in Firing Downstream Signaling and Promoting Lung Tumorigenesis

演讲者:Zhen Qin

报告标题:MA11.05 - Lysyl Oxidase Inhibition Drives Adenocarcinoma to Squamous Cell Carcinoma Transition and Promotes Drug Resistance

演讲者:YUEQING CHEN

报告标题:Lung Squamous Cell Carcinoma Prognosis Based on Ferroptosis DNA Methylation status

演讲者:Xuequan Wang

10.png11.png12.png

专场:MA13 - Building on the Past: What Will Be the Next Immunotherapy Combination?(2021.9.13)

报告标题:MA13.01 - Camrelizumab Plus Apatinib in Treatment-Naive Patients With Advanced Non-Squamous NSCLC: A Multicenter, Open-Label, Single-Arm, Phase 2 Trial

演讲者:任胜祥教授,同济大学附属上海市肺科医院

报告标题:MA13.05 - Prognostic Impact of Immune Related Adverse Events in Advanced Non-Small Cell Lung Cancer Patients with ICIs Treatment

演讲者:王慧娟教授,河南省肿瘤医院

报告标题:MA13.07 - GEMSTONE-302: A Phase 3 Study of Platinum-Based Chemotherapy with Placebo or Sugemalimab, a PD-L1 mAb, for metastatic NSCLC

演讲者:周彩存教授,同济大学附属上海市肺科医院

报告标题:MA13.08 - CHOICE-01: A Phase 3 Study of Toripalimab Versus Placebo in Combination With First-Line Chemotherapy for Advanced NSCLC

演讲者:王洁教授,中国医学科学院肿瘤医院

13.png14.png15.png

专场:MA16 - SCLC: New Targets, Biomarkers, and Systemic Therapies(2021.9.13)

报告标题:MA16.05 - PI3K/Akt/mTOR Signaling Orchestrates the Phenotypic Transition and Chemo-Resistance of Small Cell Lung Cancer

演讲者:Xuefeng Li

16.png

专场:MA17 - Diagnostics and Pulmonology(2021.9.13)

报告标题:MA17.01 - Reduced FEV1 as Prognostic Factors in Patients With Advanced NSCLC Receiving Immune Checkpoint Inhibitors

演讲者:Yi-Luen Shen

报告标题:MA17.04 - Leave Paraesophageal Lymph Node or Not in a Lung Cancer Surgery? A Propensity-Matched Analysis Based on Ten-Year Population.

演讲者:Xiaofei Wang


更多详情请至官网查看:https://library.iaslc.org/conference-program?product_id=24

本文根据官方日程仅统计“Mini Oral Session”中国专家报告内容,其他Session内容将陆续更新,如有遗漏或补充请联系肿瘤资讯-小编,微信号:oncologynews

责任编辑:MJ
排版编辑:MJ

相关阅读
评论
2021年11月13日
陈俊梅
晋中市第一人民医院 | 呼吸内科
学习使我快乐学习使我快乐学习使我快乐学习使我快乐
2021年08月11日
黄琴
江西省肿瘤医院 | 肿瘤内科
中国好声音
2021年08月11日
崔艳东
叶县人民医院 | 肿瘤科
中国好声音抢先一览